Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy
Heart May 20, 2021
Law S, Petrie A, Chacko L, et al. - This retrospective observational study was undertaken to unveil prognostic markers of disease progression in wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM), via systematic analysis of functional, biochemical and echocardiographic disease-related variables. Participants were 432 patients with wtATTR-CM, none of whom underwent disease-modifying therapy. Cox regression was employed to determine the link between mortality from the 12-month time point and alteration from diagnosis to 12 months in a variety of disease-related variables. During the first year of follow-up, an increment in N-terminal pro-B-type natriuretic peptide (NT-proBNP) of >500 ng/L, >1000 ng/L and >2000 ng/L was found in 45%, 35% and 16% of patients, respectively. Findings demonstrate NT-proBNP level alteration during the first year of follow-up as a powerful independent mortality predictor in wtATTR-CM.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries